RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “RAF Proto Oncogene Serine/Threonine Protein Kinase - Pipeline Review, H2 2017”, targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 6, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Adenocarcinoma, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.Request For Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313661
According to the recently published report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017'; RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
The report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017' outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
Browse Full Report with TOC: http://www.marketresearchhub.com/report/raf-proto-oncogene-serinethreonine-protein-kinase-proto-oncogene-c-raf-or-raf1-or-ec-27111-pipeline-review-h2-2017-report.html
Scope
- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Enquire About This Report: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1313661
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017 here
News-ID: 694761 • Views: …
More Releases from Market Research Hub - Pharmaceutical Industry
Global Enthesopathy Treatment Market Analysis by Type, Application, Top Key Play …
The global market status for Enthesopathy Treatment is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Enthesopathy Treatment Market Size, Status and Forecast 2019-2025”, which tends to deliver in-depth knowledge associated to the Enthesopathy Treatment market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market size,…
Global BioImaging Technologies Market Status, Growth Opportunity, Scope, Key Pla …
The market for BioImaging Technologies is growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global BioImaging Technologies Market Size, Status and Forecast 2019-2025” which offer details about the current trends and analysis, as well as scope for the near future. This research study also covers information about the production, consumption and market share based on different active regions. Furthermore,…
Global Drugs and Diagnostics for Hematological Disorders Market Report Overview …
Market Research Hub (MRH) has actively included a new research study titled “Global Drugs and Diagnostics for Hematological Disorders Market Size, Status and Forecast 2019-2025” to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period…
Global Biosimilar Testing and Development Services Market Report Overview 2019-2 …
Market Research Hub (MRH) has actively included a new research study titled “Global Biosimilar Testing and Development Services Market Size, Status and Forecast 2019-2025” to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until…
More Releases for RAF
Interview released with RAF Programme Manager: Reaper and Protector ahead of SMi …
SMi reports: Exclusive insights released from RAF Programme Manager: Reaper and Protector ahead of upcoming UAV Technology conference in London
As the development of new UAS technology continues to advance, and procurement and acquisition increase at a fast pace, SMi will host its fourth annual UAV Technology conference, taking place on the 30th September – 1st October 2019, in London, UK.
Ahead of the two-day conference, SMi Group caught up with…
Self Priming Pump Industry 2017 Market Research Report - Frank n Raf
As per Frank n Raf’s Research Report the Self-Priming Pumps market revenue was xx.xx Million USD in 2013, increased to xx.xx Million USD in 2017, and will touch xx.xx Million USD in 2023, with a CAGR of x.x% through the years 2018-2023. Based on the Self-Priming Pumps industrial chain, this report mainly elaborate on the definition, types, applications and major players of Self-Priming Pumps market in details. This report will…
Construction In The UAE Market – by Size, Growth, Opportunities and Key Trends …
Frank n Raf’s this Market research report provides Synopsis In real seasons, the UAE construction industry posted confident growth during the study period (20122016). Construction activity encountered a slight slowdown during 2015, owing to the collision of low oil prices. In addition, the economic slowdown in China measured the UAEs economic performance. Despite average economic growth, the countrys construction industry recorded positive growth during the review period, encouraged by the…
RAF Proto Oncogene SerineThreonine Protein Kinase (Proto Oncogene c RAF or RAF1 …
ReportsWorldwide has announced the addition of a new report title RAF Proto Oncogene SerineThreonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
According to the recently published report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017'; RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)…
Serine Protein Kinase A Raf Pharmaceutical and Pipeline Review, H2 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2017” to its report offerings. The report reviews latest news and deals related to Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) targeted therapeutics
Request…
Argentina, South Africa, France, UK RAF and more look to upgrade their Military …
SMi Reports: Military Flight Training returns to London on 11th -12th October 2017 to maximise flight training capabilities for the 21st century’s aircraft.
Military flight training experts and world leading solution providers will meet at SMi Group’s 8th annual Military Flight Training taking place in London on 11th-12th October 2017.
Military Flight Training continues to be an essential aspect for Defence Forces and military air craft manufacturers worldwide.…